AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

aap Implantate AG

Regulatory Filings Mar 7, 2002

10_rns_2002-03-07_ab24b8cd-08cd-4b90-b123-8aa91a09c102.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

News Details

Ad-hoc | 7 March 2002 08:16

aap Implantate AG english

approval for new bone replacement material in granulate form Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– approval for new bone replacement material in granulate form aap subsidiary Coripharm has received CE approval for a granulate based on Cerabone bone ceramic. The currently prevailing treatment for filling defective bone is to use endogenous bone material. However, endogenous bone material is not always available in sufficient quantity. Now, Cerabone granulate can be mixed with the bone material to increase the available quantity of the patient’s own bone. The granulate comes in three precisely defined grain sizes, making it suitable both for filling small cavities during dental, oral, orthodontic and facial surgery and for use in plastic surgery. The addition of this granulate to Coripharm’s product portfolio also provides excellent opportunities for combination with other biological components such as growth factors. One of the granulate’s distinguishing features is a highly stable internally linked pore system that resembles the structure of human bone. Another special feature of this bone replacement material is that is it very well tolerated. Merrill Lynch estimates the market volume for all bone replacement materials used in orthopedics to total roughly $420 million. Some 50% of treatment performed in this field consists of replenishing lost bone with endogenous bone. Since the results of this form of treatment can be improved considerably using the granulate, aap sees a highly promising market potential. aap Implantate AG is an innovative company in the field of metallic and biological implants for the muscular-skeletal system. In securing CE approval of Cerabone granulate, aap has demonstrated yet again its speed of innovation in extending its new biological implant business field. end of ad-hoc-announcement (c)DGAP 07.03.2002 ——————————————————————————– WKN: 506660; ISIN: DE0005066609; Index: Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 070816 Mär 02

Talk to a Data Expert

Have a question? We'll get back to you promptly.